Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

NCT05979441 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT05979441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Lead sponsor
argenx
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
September 12, 2023
Completion date
September 30, 2028
Enrollment
240 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

active idiopathic inflammatory myopathy, antisynthetase syndrome, dermatomyositis, immune-mediated necrotizing myopathy, myositis, polymyositis